Results 141 to 150 of about 35,842 (265)

Prognostic Factors for Postoperative Complications. An Aggregate Protocol for 10 Observational Studies From the Danish TRIPLE‐A Cohort of 1.2 Million Surgeries

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Postoperative complications substantially increase morbidity, mortality and healthcare costs. Understanding prognostic factors is essential for risk stratification, targeted prevention strategies, and development of prediction models.
Anders Peder Højer Karlsen   +15 more
wiley   +1 more source

Risks of gynecological and breast cancers in women with endometriosis or adenomyosis: A nationwide cohort study

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 8, Page 1607-1613, August 2026.
Endometriosis (including adenomyosis) is an inflammatory disease with lesions of endometrial tissue outside the uterus or in the uterine wall. In this study on Swedish women, endometriosis or adenomyosis was associated with persistently increased risks of breast and epithelial ovarian cancers, especially clear cell, endometrioid, and low‐grade serous ...
Louise Moberg   +6 more
wiley   +1 more source

Patterns of menopausal hormone therapy dispensing over 15 years—A Swedish register‐based cohort study

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 8, Page 1454-1467, August 2026.
In this Swedish register‐based cohort study, systemic menopausal hormone therapy dispensing decreased over 15 years, while local therapy increased. Age, cohort effects, and sociodemographic characteristics were associated with differences in dispensing patterns.
Rebecca Götze Eriksson   +9 more
wiley   +1 more source

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 8, Page 1468-1479, August 2026.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy